17 Dec 2025 Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers Investors | Therapeutics
08 Dec 2025 Avacta Announces the Preliminary Clinical Data in the Faridoxorubicin Phase 1b Trial in the Salivary Gland Cancer Cohort Investors | Therapeutics
25 Oct 2025 Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets Investors | Therapeutics
21 Oct 2025 ESMO Phase 1a data for faridoxorubicin presented by Chris Coughlin and David Liebowitz Therapeutics
19 Oct 2025 Avacta Therapeutics presents compelling Phase 1a data for faridoxorubicin and the pre|CISION® platform at the European Society of Medical Oncology Annual Congress Therapeutics
13 Oct 2025 Research & Development Spotlight Series, Episode 12 Investors | R&D Spotlights Series | Therapeutics
13 Oct 2025 Avacta to Present First Dual Payload pre|CISION® Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium Therapeutics